The underlying mechanisms for severe COVID-19 progression in people with diabetes mellitus: a critical review

Figueroa-Pizano, María D; Campa-Mada, Alma C.; Carvajal-Millan, Elizabeth; Martinez-Robinson, Karla G; Chu, Agustín Rascón

doi:10.3934/publichealth.2021057

Cited by 8 publications

(5 citation statements)

References 186 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multi-factor linear regression analysis showed that the occurrence of the disease, that is, its manifestation, is, besides HRC, significantly affected by the combinations of RFs: hypertension and hyperlipidemia; hypertension and DMT2; hyperlipidemia and smoking. These findings are in agreement with other research suggesting the significant RFs for COVID-19—hypertension, hyperlipidemia, and DMT2 ( Figueroa-Pizano et al, 2021 ; Kuo et al, 2020 ; Velavan et al, 2021 ).…”

Section: Discussionsupporting

confidence: 93%

“…There is evidence that the same RFs are significant comorbidities for COVID-19 ( Yamamoto et al, 2021 ). On the other hand, cardiovascular disease and diabetes were identified as major RFs for severe COVID-19 in older individuals ( Figueroa-Pizano et al, 2021 ; Velavan et al, 2021 ). We also examined the distribution of ABO blood groups among patients and controls, as well as the frequency of HRC within each blood group.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Homozygous-Recessive Characteristics as a Biomarker of Predisposition for COVID-19

et al. 2023

View full text Add to dashboard Cite

Coronavirus disease (COVID-19), a new form of severe acute respiratory syndrome, has caused a global pandemic. The aim of this study was to analyze homozygous-recessive characteristics (HRC) in the group of COVID-19 patients, considering their gender, forms of the disease (mild and severe symptoms), risk factors: hypertension, diabetes mellitus type 2, hyperlipidemia, smoking habits, and the distribution of ABO blood group. Using the HRC test, we analyzed 20 HRCs in a sample of 321 individuals: 205 patients and 116 controls. The average HRC in patients was significantly higher than controls, as well as in patients with severe symptoms compared to patients with mild symptoms. The patients with higher HRC (cut-off ≤5.5) experienced a significantly increased risk of disease of 2.3 times ( OR = 2.315, p < .0005). Our results indicate that the HRC test could be used as a screening in recognizing predisposition for COVID-19.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Homozygous-Recessive Characteristics as a Biomarker of Predisposition for COVID-19

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Substantial evidence points towards a greater risk of more severe COVID-19 outcomes in individuals with T2D and obesity, two frequently co-existing conditions [41][42][43]. As a routinely used medication in T2D, metformin has not only a hypoglycemic activity, but also impacts the gut microbiome by enhancing the SCFAs levels, which harbor antiinflammatory activity [44].…”

Section: Discussionmentioning

confidence: 99%

Impact of COVID-19 on the Microbiome and Inflammatory Status of Type 2 Diabetes Patients

et al. 2023

View full text Add to dashboard Cite

The severe acute respiratory syndrome–related coronavirus 2 (SARS-CoV-2) pandemic has advanced our understanding of the host–microbiome–virus interplay. Several studies in various geographical regions report that SARS-CoV-2 infection disrupts the intestinal microbiota, allowing pathogenic bacteria such as Enterobacteriaceae to thrive, and triggering more severe disease outcomes. Here, we profile the microbiota of 30 individuals, 15 healthy controls and 15 type 2 diabetes (T2D) patients, before and after coronavirus disease 2019 (COVID-19). Despite similar viral loads in both patients and controls, SARS-CoV-2 infection led to exacerbated microbiome changes in T2D patients, characterized by higher levels of Enterobacteriaceae, loss of butyrate producers and an enrichment in fungi such as Candida spp. and Aspergillus spp. Several members of the microbiota were associated with more severe clinical and inflammatory (IL-8 and IL-17) parameters. Future studies to delineate the connection between cytokine release and microbiota disturbances will enhance our understanding of whether these microbial shifts directly impact the cytokine storm in COVID-19 patients or whether they are consecutive to the critical disease.

show abstract

“…The chronic inflammatory condition in T2D is considered the underlying mechanism for the “cytokine storm” complication and worsens the outcomes of COVID-19 [ 160 ]. It is assumed that hyperinflammation may result in multiorgan failure, a general complication in critical COVID-19 cases [ 161 ].…”

Section: Immunoregulation Gut Microbiota and Covid-19mentioning

confidence: 99%

Immunoregulatory Intestinal Microbiota and COVID-19 in Patients with Type Two Diabetes: A Double-Edged Sword

Petakh

Kamyshna

Nykyforuk

et al. 2022

Viruses

View full text Add to dashboard Cite

Coronavirus disease 2019, or COVID-19, is a major challenge facing scientists worldwide. Alongside the lungs, the system of organs comprising the GI tract is commonly targeted by COVID-19. The dysbiotic modulations in the intestine influence the disease severity, potentially due to the ability of the intestinal microbiota to modulate T lymphocyte functions, i.e., to suppress or activate T cell subpopulations. The interplay between the lungs and intestinal microbiota is named the gut–lung axis. One of the most usual comorbidities in COVID-19 patients is type 2 diabetes, which induces changes in intestinal microbiota, resulting in a pro-inflammatory immune response, and consequently, a more severe course of COVID-19. However, changes in the microbiota in this comorbid pathology remain unclear. Metformin is used as a medication to treat type 2 diabetes. The use of the type 2 diabetes drug metformin is a promising treatment for this comorbidity because, in addition to its hypoglycemic action, it can increase amount of intestinal bacteria that induce regulatory T cell response. This dual activity of metformin can reduce lung damage and improve the course of the COVID-19 disease.

show abstract

The underlying mechanisms for severe COVID-19 progression in people with diabetes mellitus: a critical review

Cited by 8 publications

References 186 publications

Homozygous-Recessive Characteristics as a Biomarker of Predisposition for COVID-19

Homozygous-Recessive Characteristics as a Biomarker of Predisposition for COVID-19

Impact of COVID-19 on the Microbiome and Inflammatory Status of Type 2 Diabetes Patients

Immunoregulatory Intestinal Microbiota and COVID-19 in Patients with Type Two Diabetes: A Double-Edged Sword

Contact Info

Product

Resources

About